Post-earnings recap
Reported
Thu, Aug 7, 2025
EPS actual
$0.28
EPS est.
$-0.35
EPS surprise
+179.10%
1-day move
+1.11%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The strong EPS beat indicates that 10X Genomics is managing costs effectively and possibly benefiting from increased demand for their products. The stock's 1.11% increase reflects investor confidence in the company's performance, despite the lack of revenue data and guidance. This quarter's results may position the company favorably for future growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.28 | N/A | +179.10% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. They emphasized the importance of maintaining a strong market position.
We are pleased with our EPS performance this quarter.
Our focus remains on innovation and expanding our market presence.